Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Am J Gastroenterol ; 96(1): 89-94, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11197294

RESUMEN

OBJECTIVE: Bleeding is a serious complication of peptic ulcer. Endoscopic injection therapy is accepted as a homeostatic endoscopic treatment in acute nonvariceal of upper GI hemorrhages, particularly in bleeding peptic ulcers. The risk of rebleeding is predicted by the endoscopic appearance of ulcer features classified according to Forrest's criteria. METHODS: Two hundred twenty-three patients were selected from 1,003 emergency upper endoscopies for GI bleeding. According to Forrest's criteria, 99 well-matched patients with ulcers F1 and F2 were considered at risk of rebleeding; 54 patients (group A) received local ulcer injection of epinephrine solution 1:10,000, whereas (group B) patients were treated with local epinephrine injection and then with endoscopic Hemoclips. (1) We considered the control of bleeding, the number of rebleeding episodes, the need for emergency surgery, and mortality. RESULTS: Bleeding ulcers stopped completely in 83.3% group A patients, and in 95.6% group B patients (p = not significant). In a subset of F1b patients the rebleeding rate was 31 % for group A and 0% for group B (p < 0.05). There was no mortality as a result of the procedure. There was a trend toward reducing surgery in favor of the combined therapy (0% vs 7.4%). No differences were found in transfusion requirements or mean hospitalization days. CONCLUSIONS: We conclude that endoscopic injection of l:10,000 epinephrine solution alone and epinephrine solution plus application of Hemoclips are equivalent therapies in treating bleeding and rebleeding from peptic ulcers. There was no difference between therapies in terms of need for surgery or mortality. Possibly combination therapy is more effective in treating ulcers that are actively oozing.


Asunto(s)
Úlcera Duodenal/terapia , Epinefrina/administración & dosificación , Técnicas Hemostáticas/instrumentación , Úlcera Péptica Hemorrágica/terapia , Úlcera Gástrica/terapia , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Estudios de Casos y Controles , Estudios de Cohortes , Úlcera Duodenal/diagnóstico , Úlcera Duodenal/tratamiento farmacológico , Duodenoscopía/métodos , Femenino , Gastroscopía/métodos , Humanos , Inyecciones Intralesiones , Masculino , Persona de Mediana Edad , Úlcera Péptica Hemorrágica/diagnóstico , Úlcera Péptica Hemorrágica/tratamiento farmacológico , Sensibilidad y Especificidad , Úlcera Gástrica/diagnóstico , Úlcera Gástrica/tratamiento farmacológico , Resultado del Tratamiento
2.
Recent Results Cancer Res ; 156: 116-24, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-10802871

RESUMEN

The effect of eradication of Helicobacter pylori on early stage gastric low-grade MALT lymphoma in 76 patients with follow-up of at least 1 year (12-63 months, mean 28) is reported. No regression was found in five cases after 12-48 months. In one case surgical resection detected the involvement of perigastric lymph nodes overlooked by endoscopic ultrasonography (EUS). Neither progression of the disease nor a high-grade component was documented by repeated gastric mappings, EUS and complete stagings in the other four cases. After histological remission five relapses of low-grade and one relapse of high-grade MALT lymphoma were found 12-48 months after eradication. Subsequent histological remission, without any additional therapy, was found in three relapsed cases. A rapid and persistent histological remission was obtained in 56 patients (73%). A late remission was observed in six cases. Monoclonal remission was found in half of the patients and was frequently delayed. Persistent monoclonality was associated with histological remission in the vast majority of patients. Our data confirm H. pylori eradication as the first choice therapy for early stage gastric low-grade MALT lymphoma and recommend extensive bioptic mapping and endoscopic sonography both in the local staging and in the regression evaluation. The rare cases of late remission encourage us to wait for at least 1 year after eradication of H. pylori. Longer follow-up studies will clarify the meaning of histological relapse/persistence and late remission. The study of non-responder cases could show us a step in lymphomagenesis.


Asunto(s)
Infecciones por Helicobacter/tratamiento farmacológico , Linfoma de Células B de la Zona Marginal/patología , Neoplasias Gástricas/patología , Anciano , Anciano de 80 o más Años , Antibacterianos/uso terapéutico , Estudios de Evaluación como Asunto , Femenino , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/microbiología , Helicobacter pylori/aislamiento & purificación , Humanos , Italia , Linfoma de Células B de la Zona Marginal/tratamiento farmacológico , Linfoma de Células B de la Zona Marginal/microbiología , Masculino , Persona de Mediana Edad , Recurrencia , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/microbiología , Resultado del Tratamiento
3.
Am J Gastroenterol ; 89(10): 1815-22, 1994 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-7942674

RESUMEN

OBJECTIVES: Gastroesophageal bleeding from varices is the most life-threatening complication in liver cirrhosis with portal hypertension. Since its first application, endoscopic sclerotherapy seems to be the most widely applicable procedure to stop the bleeding and to prevent recurrences. The aim of this study was to ascertain the role of some factors as predictors of survival in different groups of cirrhotic patients. METHODS: At the time of their first hemorrhage from esophageal varices, 184 patients with portal hypertension from cirrhosis were treated by endoscopic sclerotherapy using a combined intraparavariceal procedure and Polidocanol 1% as sclerosing agent. RESULTS: The follow-up range was 1-106 months (mean, 28.2 months), and 84 patients were still alive (45.7%), 97 had died (52.7%), and three had withdrawn (1.6%) at the end of the period. The major cause of death was bleeding, and 35 patients died in the first 6 wk after sclerotherapy. Using Cox proportional hazard models, Child's grading was the most important prognostic factor of both short-term (first 6 wk) and medium/long-term survival (after the first 6 wk up to 5 years). Complete eradication of varices, too, was associated with both short- and long-term survival, whereas age, sex, etiology of cirrhosis, and the presence of esophageal stenosis as a side effect of sclerotherapy were not. The type of sclerotherapy (elective vs emergent) was associated with survival, but it was not independent from Child's grade, because only patients in Child C treated electively showed a better prognosis than those treated in emergency. CONCLUSIONS: We can conclude that patients with severe liver disease (Class C) have poor prognosis, and complete eradication represents an aim because it seems to be protective against the risk of dying.


Asunto(s)
Várices Esofágicas y Gástricas/mortalidad , Cirrosis Hepática/complicaciones , Escleroterapia , Várices Esofágicas y Gástricas/complicaciones , Várices Esofágicas y Gástricas/terapia , Esofagoscopía , Femenino , Hemorragia Gastrointestinal/etiología , Hemorragia Gastrointestinal/terapia , Humanos , Hipertensión Portal/complicaciones , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Escleroterapia/métodos , Análisis de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA